Cavosonstat

Drug Profile

Cavosonstat

Alternative Names: N 91115

Latest Information Update: 09 Feb 2017

Price : $50

At a glance

  • Originator N30 Pharma
  • Developer Nivalis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators; Glutathione-independent formaldehyde dehydrogenase inhibitors; Nitric oxide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 01 Jan 2017 Nivalis Therapeutics completes a phase I multiple-ascending dose trial in Healthy volunteers in USA (NCT02934139)
  • 28 Nov 2016 Topline efficacy and safety data from a phase II trial in Cystic fibrosis released by Nivalis
  • 28 Nov 2016 Nivalis completes a phase II trial in Cystic fibrosis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top